» Articles » PMID: 39156568

A Review of Deep Learning Methods for Ligand Based Drug Virtual Screening

Overview
Journal Fundam Res
Date 2024 Aug 19
PMID 39156568
Authors
Affiliations
Soon will be listed here.
Abstract

Drug discovery is costly and time consuming, and modern drug discovery endeavors are progressively reliant on computational methodologies, aiming to mitigate temporal and financial expenditures associated with the process. In particular, the time required for vaccine and drug discovery is prolonged during emergency situations such as the coronavirus 2019 pandemic. Recently, the performance of deep learning methods in drug virtual screening has been particularly prominent. It has become a concern for researchers how to summarize the existing deep learning in drug virtual screening, select different models for different drug screening problems, exploit the advantages of deep learning models, and further improve the capability of deep learning in drug virtual screening. This review first introduces the basic concepts of drug virtual screening, common datasets, and data representation methods. Then, large numbers of common deep learning methods for drug virtual screening are compared and analyzed. In addition, a dataset of different sizes is constructed independently to evaluate the performance of each deep learning model for the difficult problem of large-scale ligand virtual screening. Finally, the existing challenges and future directions in the field of virtual screening are presented.

Citing Articles

New strategies to enhance the efficiency and precision of drug discovery.

An Q, Huang L, Wang C, Wang D, Tu Y Front Pharmacol. 2025; 16:1550158.

PMID: 40008135 PMC: 11850385. DOI: 10.3389/fphar.2025.1550158.


The role of artificial intelligence in drug screening, drug design, and clinical trials.

Wu Y, Ma L, Li X, Yang J, Rao X, Hu Y Front Pharmacol. 2024; 15:1459954.

PMID: 39679365 PMC: 11637864. DOI: 10.3389/fphar.2024.1459954.


Causal enhanced drug-target interaction prediction based on graph generation and multi-source information fusion.

Qiao G, Wang G, Li Y Bioinformatics. 2024; 40(10).

PMID: 39312682 PMC: 11639159. DOI: 10.1093/bioinformatics/btae570.

References
1.
Yuan W, Chen G, Chen C . FusionDTA: attention-based feature polymerizer and knowledge distillation for drug-target binding affinity prediction. Brief Bioinform. 2021; 23(1). DOI: 10.1093/bib/bbab506. View

2.
Kalakoti Y, Yadav S, Sundar D . TransDTI: Transformer-Based Language Models for Estimating DTIs and Building a Drug Recommendation Workflow. ACS Omega. 2022; 7(3):2706-2717. PMC: 8792915. DOI: 10.1021/acsomega.1c05203. View

3.
Ozturk H, Ozgur A, Ozkirimli E . DeepDTA: deep drug-target binding affinity prediction. Bioinformatics. 2018; 34(17):i821-i829. PMC: 6129291. DOI: 10.1093/bioinformatics/bty593. View

4.
Du B, Qin Y, Jiang Y, Xu Y, Yiu S, Yu H . Compound-protein interaction prediction by deep learning: Databases, descriptors and models. Drug Discov Today. 2022; 27(5):1350-1366. DOI: 10.1016/j.drudis.2022.02.023. View

5.
Szklarczyk D, Santos A, von Mering C, Jensen L, Bork P, Kuhn M . STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2015; 44(D1):D380-4. PMC: 4702904. DOI: 10.1093/nar/gkv1277. View